Anticholinergic medication use and dementia: latest evidence and clinical implications.

Article Details

Citation

Copy to clipboard

Gray SL, Hanlon JT

Anticholinergic medication use and dementia: latest evidence and clinical implications.

Ther Adv Drug Saf. 2016 Oct;7(5):217-224. doi: 10.1177/2042098616658399. Epub 2016 Jul 18.

PubMed ID

27695623 [ View in PubMed

]

Abstract

Use of medications with anticholinergic activity is widespread in older adults. Several studies have highlighted that anticholinergic use may be associated with an increased risk of dementia. The objective of this narrative review is to describe and evaluate studies of anticholinergic medication use and dementia and provide practical suggestions for avoiding use of these medications in older adults. A comprehensive review of the literature, citations from recent reviews and the author's personal files was conducted. Four studies were found that evaluated anticholinergic use and dementia as the primary outcome. Three studies focused on overall anticholinergic medication use and reported a statistically significantly increased risk of Alzheimer's disease or dementia. In one study, dementia risk was primarily found with higher cumulative doses; people using anticholinergic medications at the minimum effective dose recommended for older adults for at least 3 years were at highest risk. In contrast, a study conducted in nursing-home residents with depression did not find that paroxetine [a highly anticholinergic selective serotonin reuptake inhibitor antidepressant, (SSRI)] increased risk for dementia compared with other SSRIs (without anticholinergic activity). Further study is needed to understand the mechanism by which anticholinergic medications may increase risk. In conclusion, there is evidence from three observational studies suggesting that anticholinergic medications may increase dementia risk. Given this potential risk and the myriad of other well-known adverse effects (i.e. constipation, blurred vision, urinary retention, and delirium) associated with anticholinergic medications, it is prudent for prescribers and older adults to minimize use of these medications and consider alternatives when possible.

DrugBank Data that Cites this Article

Drugs

Paroxetine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Paroxetine	Muscarinic acetylcholine receptor (Protein Group)	Protein group	Humans	Unknown	Inhibitor	Details